The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Eisenbarth (1986) · doi:10.1056/nejm198605223142106 · Cited by 1,659
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Pathologic anatomy of the pancreas in juvenile diabetes mellitus
Gepts, W. (1965) · Diabetes · doi:10.2337/diab.14.10.619 · Cited by 1,345 · cited 1×
“Since the beta cell mass is already markedly reduced at clinical onset of type 1 diabetes [18, 19], it is likely that any immune-modulating intervention will have to be associated with, or followed by, a beta cell replacement therapy, as recently tested in rodents [20]; a combination with other methods for tolerance-i…”
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Self-citationProgressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Gómez‐Reino, J. J., Carmona, L., Valverde, V. R., Mola, E. M., & Montero, M. D. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11137 · Cited by 1,013
β-Cell Glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes.
Robertson, R. P., Harmon, J., Tran, P. O. T., & Poitout, V. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s119 · Cited by 914
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.832 · Cited by 695
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
Chatenoud, L., Thervet, E., Primo, J., & Bach, J. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.123 · Cited by 664
Self-citationHerold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., & Bluestone, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1763 · Cited by 634
CD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Self-citation(1989) · New England Journal of Medicine · doi:10.1056/nejm198905253202117 · Cited by 269
In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies
Xu, D., Alegre, M.-L., Varga, S. S., Rothermel, A. L., Collins, A. M., Pulito, V. L., Hanna, L. S., Dolan, K. P., Parren, P. W. H. I., Bluestone, J. A., et al. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1617 · Cited by 238
THE DCCT RESEARCH GROUP (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-30 · Cited by 220
Bolt, S., Routledge, E., Lloyd, I., Chatenoud, L., Pope, H., Gorman, S. D., Clark, M., & Waldmann, H. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230216 · Cited by 218
Self-citationKilpatrick, E. S., Rigby, A. S., Goode, K., & Atkin, S. L. (2007) · Diabetologia · doi:10.1007/s00125-007-0820-z · Cited by 209
Keymeulen, B., Gillard, P., Mathieu, C., Movahedi, B., Maleux, G., Delvaux, G., Ysebaert, D., Roep, B., Vandemeulebroucke, E., Marichal, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608141103 · Cited by 176
Self-citationSherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C. (2007) · Endocrinology · doi:10.1210/en.2007-0358 · Cited by 169 · cited 1×
“Since the beta cell mass is already markedly reduced at clinical onset of type 1 diabetes [18, 19], it is likely that any immune-modulating intervention will have to be associated with, or followed by, a beta cell replacement therapy, as recently tested in rodents [20]; a combination with other methods for tolerance-i…”
Pancreatic beta cells in insulin‐dependent diabetes
PIPELEERS, D. G., & Ling, Z. (1992) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610080303 · Cited by 144
Self-citationType 1 Diabetes and Latent Autoimmune Diabetes in Adults: One End of the Rainbow
Leslie, R. D. G., Williams, R., & Pozzilli, P. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1623 · Cited by 142
Decochez, K., Tits, J., Coolens, J.-L., Gaal, L. V., Krzentowski, G., Winnock, F., Anckaert, E., Weets, I., PIPELEERS, D. G., & Gorus, F. (2000) · Diabetes Care · doi:10.2337/diacare.23.6.838 · Cited by 106
Self-citationNewell, B., Dilly, S., Finlayson, C., Gandhi, M., & Lakhani, S. (2009) · CRC Press eBooks · doi:10.1201/b13541-43 · Cited by 100
Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study.
Parving, H. ‐., Tarnow, L., Nielsen, F. S., Rossing, P. R., Mandrup-Poulsen, T. R., Østerby, R., & Nerup, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.478 · Cited by 96
Palmer, J. P., & Hirsch, I. B. (2003) · Diabetes Care · doi:10.2337/diacare.26.2.536 · Cited by 93
Treatment of Recalcitrant Plaque Psoriasis with a Humanized Non-depleting Antibody to CD4
Bachelez, H., Flageul, B., Dubertret, L., Fraitag, S., Grossman, R., Brousse, N., Poisson, D., Knowles, R. W., Wacholtz, M. C., Haverty, T. P., et al. (1998) · Journal of Autoimmunity · doi:10.1006/jaut.1997.0175 · Cited by 58
Self-citationTran, G. T., Carter, N. M., He, X. Y., et al. (2001) · International Immunology · doi:10.1093/intimm/13.9.1109 · Cited by 54
Prevention of type 1 diabetes: the time has come
Sherr, J. L., Sosenko, J. M., Skyler, J. S., & Herold, K. C. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0832 · Cited by 48
The β Cell Population in Type 1 Diabetes
PIPELEERS, D. G., Veld, P. I. '., Pipeleers-Marichal, M. A., & Gorus, F. (2008) · Novartis Foundation symposium · doi:10.1002/9780470697405.ch3 · Cited by 26
Self-citationImmunomodulation with human recombinant autoantigens
Lernmark, Å., & Agardh, C.-D. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.08.015 · Cited by 24
Calibration of ion-exchange HPLC measurements of glycohemoglobin: effect on interassay precision
Gerlo, E., & Gorus, F. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.12.2353 · Cited by 15
Self-citation
Cited by
Poznyak, A., Grechko, A. V., Poggio, P., Myasoedova, V. A., Alfieri, V., & Orekhov, A. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051835 · Cited by 1,163
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Todd, J. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.001 · Cited by 560
Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., Bode, B., Aronoff, S., Holland, C., Carlin, D., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60931-8 · Cited by 493
Herold, K. C., Gitelman, S. E., Ehlers, M. R., Gottlieb, P. A., Greenbaum, C. J., Hagopian, W., Boyle, K. D., Keyes-Elstein, L., Aggarwal, S., Phippard, D., et al. (2013) · Diabetes · doi:10.2337/db13-0345 · Cited by 411
Metadata
- Authors
- Keymeulen, B., Walter, M., Mathieu, C., Kaufman, L., Gorus, F., Hilbrands, R., Vandemeulebroucke, E., Van de Velde, U., Crenier, L., De Block, C., Candon, S., Waldmann, H., Ziegler, A. G., Chatenoud, L., & Pipeleers, D.
- Venue
- Diabetologia
- Published
- 2010-01-14
- Volume
- 53
- Issue
- 4
- Pages
- 614-623
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2140213275
- Cited by
- 317
- References
- 36
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.